Health Economics›Ovarian cancer›Relapsed or recurrent disease platinum-sensitive

Relapsed or recurrent disease platinum-sensitive

Ovarian cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Olaparib monotherapy Variant #01	HRD	R 19 741	28d	~13.4 mo	~40.9 mo	~2	~R 39 483 PFS proxy · indirect	8
Topotecan monotherapy Variant #01	HRD	R 18 138	21d	~4.0 mo	~13.4 mo	~11	~R 199 522 PFS proxy · indirect	9
Pegylated liposomal doxorubicin monotherapy Variant #02	HRD	R 8 000	28d	~3.9 mo	~13.5 mo	~6	~R 48 000 PFS proxy · indirect	18
Gemcitabine monotherapy Variant #01	HRD	R 1 672	21d	~3.3 mo	~15.0 mo	~7	~R 11 705 PFS proxy · indirect	4
Paclitaxel monotherapy Variant #02	HRD	R 734	28d	~4.4 mo	~14.0 mo	~7	~R 5 141 PFS proxy · indirect	18
Carboplatin monotherapy Variant #01	HRD	R 535	21d	5.8 mo	21.0 mo	2	R 1 070 PFS proxy	2

6 of 6 regimens shown